[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE421883T1 - Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline - Google Patents

Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Info

Publication number
ATE421883T1
ATE421883T1 AT99969030T AT99969030T ATE421883T1 AT E421883 T1 ATE421883 T1 AT E421883T1 AT 99969030 T AT99969030 T AT 99969030T AT 99969030 T AT99969030 T AT 99969030T AT E421883 T1 ATE421883 T1 AT E421883T1
Authority
AT
Austria
Prior art keywords
glucan
compositions containing
specific immunoglobulins
containing beta
beta
Prior art date
Application number
AT99969030T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Fattom
Robert Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of ATE421883T1 publication Critical patent/ATE421883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99969030T 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline ATE421883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
ATE421883T1 true ATE421883T1 (de) 2009-02-15

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969030T ATE421883T1 (de) 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Country Status (11)

Country Link
US (1) US6355625B1 (de)
EP (1) EP1121135B1 (de)
AT (1) ATE421883T1 (de)
AU (1) AU6033299A (de)
CA (1) CA2344166C (de)
CY (1) CY1109437T1 (de)
DE (1) DE69940371D1 (de)
DK (1) DK1121135T3 (de)
ES (1) ES2321892T3 (de)
PT (1) PT1121135E (de)
WO (1) WO2000015238A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2002058711A1 (en) 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CA2496508C (en) 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
WO2006085895A2 (en) * 2004-05-10 2006-08-17 Biopolymer Engineering, Inc. Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
CA2584290A1 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Staphylococcal immunogenic compositions
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
AU2005324448A1 (en) * 2005-01-10 2006-07-20 Glaxosmithkline Biologicals Sa Method of treating Staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20090214562A1 (en) * 2005-05-03 2009-08-27 Karel Steven J Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
JP5296531B2 (ja) * 2005-05-05 2013-09-25 センシエント フレイバーズ エルエルシー βグルカン及びマンナンの製造
CA2611023A1 (en) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007113222A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2007259415B2 (en) 2006-06-12 2013-09-26 Glaxosmithkline Biologicals Sa Use of alpha-toxin for treating and preventing Staphylococcus infections
EP2208787A1 (de) 2009-01-19 2010-07-21 Université de Liège Rekombinantes alpha-Hämolysin-Polypeptid von Staphylococcus aureus, mit einer Deletion in der Stammdomäne und eingefügten heterologen Sequenzen
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
HUE057713T2 (hu) 2009-04-03 2022-05-28 Univ Chicago A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
HRP20220068T1 (hr) 2010-05-05 2022-04-15 New York University Staphylococcus aureus leukocidini, terapijski pripravci, i njihova uporaba
WO2012003474A2 (en) 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
HUE051832T2 (hu) 2011-06-19 2021-03-29 Univ New York Staphylococcus aureus fertõzések és a kapcsolódó állapotok kezelésére és megelõzésére szolgáló módszerek
CN103764228B (zh) 2011-06-19 2017-09-08 纽约大学 作为新的抗炎剂和杀菌剂的白细胞毒素e/d
JP6317670B2 (ja) 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
BR112014026808A2 (pt) 2012-04-26 2018-05-15 Univ Chicago composições e métodos relacionados a anticorpos que neutralizam atividade de coagulase durante doença por staphylococcus aureus
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
ES2661393T3 (es) * 2012-04-30 2018-03-28 Biothera, Inc. Preparación inmunoterapéutica de beta glucano
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
US20170281744A1 (en) 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
JP7117244B2 (ja) 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
WO2023192998A1 (en) 2022-04-01 2023-10-05 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
EP0648127B1 (de) * 1991-11-22 2003-04-16 Univax Biologics Incorporated Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
WO1996014873A2 (en) 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
DE69940371D1 (de) 2009-03-19
WO2000015238A9 (en) 2000-10-12
ES2321892T3 (es) 2009-06-12
US6355625B1 (en) 2002-03-12
DK1121135T3 (da) 2009-03-23
CA2344166A1 (en) 2000-03-23
EP1121135B1 (de) 2009-01-28
EP1121135A4 (de) 2005-03-16
CA2344166C (en) 2008-11-18
WO2000015238A1 (en) 2000-03-23
EP1121135A1 (de) 2001-08-08
CY1109437T1 (el) 2014-08-13
AU6033299A (en) 2000-04-03
PT1121135E (pt) 2009-03-05
WO2000015238B1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DE60005953D1 (de) Stapelbare statische mischelemente
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
ATE355288T1 (de) Verbindungen und therapeutische methoden
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
EA200100700A1 (ru) Гены и белки и их применение
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
NO20022949L (no) Attenuerte mikroorganismer for behandling av infeksjon
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
ATE212839T1 (de) Hämoregulatorische verbindungen
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121135

Country of ref document: EP